Progress on development of the live BCG recombinant vaccine vehicle for combined vaccine delivery.
BCG, the current vaccine for tuberculosis, has been administered to approximately three billion people. This live vaccine has a low incidence of serious side effects and can be given at birth. Within the past six years, systems for the manipulation and expression of foreign genes in mycobacteria have been developed, allowing the evaluation of rBCG as a vaccine delivery vehicle for heterologous antigens. Recent studies from our group have shown that rBCG expressing outer surface protein A of Borrelia burgdorferi can completely protect mice from an intradermal challenge with this organism. Immune responses protective against Streptococcus pneumoniae challenge have also been achieved by immunization of mice with rBCG expressing PspA. The simplest means of administering multiple vaccine antigens in a rBCG vehicle would be to coexpress these simultaneously in the same BCG recombinant. Currently two general classes of vectors exist for the expression of foreign proteins in BCG: shuttle plasmid vectors, which replicate extrachromosomally in mycobacteria, and shuttle "phasmid" vectors, which integrate as a single copy into the mycobacterial chromosome by means of vector-encoded integration functions of the lysogenic mycobacteriophage L5. The genetic capacity of the multicopy plasmid vectors may be 20 kb or more, while the potential exists for stable integration of much larger amounts of DNA into the mycobacterial genome (L5 itself is 52 kb). Additionally, these two expression systems can have the compatibility to coexist in a single BCG cell. Otitis media is caused by infections of the middle ear chiefly with either S. pneumoniae or H. influenzae. Thus, an effective vaccine would necessarily include antigens from both these pathogens. Our initial attempt at construction of a BCG multivaccine vehicle was to express proteins from each of these pathogens from the same multicopy plasmid. We have recently succeeded in coexpressing the S. pneumoniae PspA and H. influenzae PAL proteins in BCG. Future work will address how the biochemical characterization of and immune responses to the recombinant antigens of the "bivalent" rBCG:PspA/PAL vaccine compare to those of the respective "monovalent" rBCG vaccines.
Hanson
M S
MS
MedImmune, Inc., Gaithersburg, Maryland 20878, USA.
Lapcevich
C V
CV
Haun
S L
SL
D000942:Antigens, Bacterial / Q000235:genetics; D001500:BCG Vaccine / Q000737:chemistry* / Q000276:immunology; D001426:Bacterial Proteins / Q000235:genetics / Q000276:immunology; D006193:Haemophilus influenzae / Q000276:immunology; D006801:Humans; D010033:Otitis Media / Q000517:prevention & control; D013296:Streptococcus pneumoniae / Q000276:immunology; D014170:Transformation, Genetic; D017778:Vaccines, Combined / Q000737:chemistry* / Q000276:immunology; D014614:Vaccines, Synthetic / Q000737:chemistry* / Q000276:immunology
D000942:Antigens, Bacterial; D001500:BCG Vaccine; D001426:Bacterial Proteins; D017778:Vaccines, Combined; D014614:Vaccines, Synthetic